SCHEMBL4937584

SCHEMBL4937584

CC(C)(C)OC(=O)C(C(=O)O)C(N)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.42
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 4/20 0.41
SLC7A5 Q01650 1/20 0.40
AAK1 Q2M2I8 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
CYP2D6 P10635 2/20 0.38
SRC P12931 1/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
CYP1A2 P05177 1/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AOC3 Q16853 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27665873 1.00 DPP4 (0.42) DPP4ATML3MBTL1KMT2ASLC7A5
SCHEMBL27564999 1.00 DPP4 (0.42) DPP4ATML3MBTL1KMT2ASLC7A5
SCHEMBL28911807 0.91 PTGS2 (0.46) KMT2ASLC7A5CTSSCTSKMAPT
SCHEMBL28555152 0.91 PTGS2 (0.46) KMT2ASLC7A5CTSSCTSKMAPT
SCHEMBL28261977 0.89 ATM (0.44) DPP4ATML3MBTL1KMT2AAAK1
SCHEMBL28837744 0.89 DPP4 (0.41) DPP4ATML3MBTL1KMT2ASLC7A5
SCHEMBL5844667 0.87 KIF11 (0.37) KMT2ASLC7A5ALDH1A1SMN1; SMN2
SCHEMBL2844018 0.87 SLC7A5 (0.37) KMT2ASLC7A5CTSSCTSKSRC
SCHEMBL27513958 0.86 L3MBTL1 (0.47) DPP4ATML3MBTL1KMT2ASLC7A5
SCHEMBL25220978 0.86 SMN1; SMN2 (0.38) DPP4KMT2ASLC7A5CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113121396-B Degradable polydiseleno-containing polydopamine and preparation method and application thereof 华南理工大学 2022-06-10 CN claimed
CN-113121396-A Degradable polydiseleno-containing polydopamine and preparation method and application thereof 华南理工大学 2021-07-16 CN claimed
CN-113121396-B Degradable polydiseleno-containing polydopamine and preparation method and application thereof 华南理工大学 2022-06-10 CN disclosed
CN-111018723-B Preparation and detection method of dapoxetine hydrochloride isomer impurity 盖天力医药控股集团制药股份有限公司 2022-03-08 CN disclosed
CN-113121396-A Degradable polydiseleno-containing polydopamine and preparation method and application thereof 华南理工大学 2021-07-16 CN disclosed
CN-111018723-A Preparation and detection method of dapoxetine hydrochloride isomer impurity 盖天力医药控股集团制药股份有限公司 2020-04-17 CN disclosed
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-09-10 US disclosed
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2019-08-15 US disclosed
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-01-01 US disclosed
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2018-02-22 US disclosed
US-9669015-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2017-06-06 US disclosed
CN-101679418-A [2,6] naphthyridines compounds as protein kinase inhibitors NOVARTIS AG 2010-03-24 CN disclosed
CN-101597284-A A kind of preparation method of antineoplastic compound BEIJING LAIDESAILUSEN PHARMACE (CN) 2009-12-09 CN disclosed
CN-101389609-A Hydantoin-based kinase inhibitors HOFFMANN LA ROCHE (CH) 2009-03-18 CN disclosed
CN-101253147-A Organic compounds NOVARTIS PHARMA AG (CH) 2008-08-27 CN disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed
EP-1867649-A1 PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2007-12-19 EP disclosed
CN-101023079-A Substituted hydantoins for the treatment of cancer HOFFMANN LA ROCHE (CH) 2007-08-22 CN disclosed
CN-1694874-A Benzodiazepine * derivatives and pharmaceutical compositions containing them ARROW THERAPEUTICS LTD (GB) 2005-11-09 CN disclosed
CN-1678372-A Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL MYERS SQUIBB CO (US) 2005-10-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNFRSF9, TNFRSF1A, NGFR DPP4 2779/4885ATM 4800/4885L3MBTL1 3715/4885
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNF, TNFRSF1A, TNFRSF9 DPP4 3253/4885ATM 4748/4885L3MBTL1 3964/4885
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNFRSF1A, TNFRSF9, NGFR DPP4 2953/4885ATM 4791/4885L3MBTL1 3663/4885
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DPP4 3193/4885ATM 4751/4885L3MBTL1 4000/4885
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DPP4 3253/4885ATM 4748/4885L3MBTL1 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.